Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
暂无分享,去创建一个
D. Katsaros | A. Sapino | R. Senetta | P. Cassoni | M. Aglietta | A. Gambino | F. Maggiorotto | F. Borella | G. Valabrega | E. Ghisoni | G. Mittica | G. Giannone | S. Genta | V. Tuninetti | G. Scotto | M. Goia | M. Fonte | Chiara Eusebi | Marina Momi | Margherita Goia
[1] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[2] G. Lou,et al. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. , 2018, Gynecologic oncology.
[3] J. Joo,et al. Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer: A Single Institutional Experience of 56 Patients , 2018, International Journal of Gynecologic Cancer.
[4] N. Popitsch,et al. Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations , 2017, Journal of Neuro-Oncology.
[5] A. Sapino,et al. Androgen receptor status predicts development of brain metastases in ovarian cancers , 2017, Oncotarget.
[6] N. Biglia,et al. Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19). , 2016, Gynecologic oncology.
[7] C. Sotiriou,et al. The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data , 2016, Clinical Cancer Research.
[8] Luzhe Sun,et al. The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications , 2016, Oncotarget.
[9] Kai Xu,et al. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis , 2016, Oncotarget.
[10] P. Martin-Hirsch,et al. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival , 2016, British Journal of Cancer.
[11] M. Trippel,et al. Androgen receptor status is highly conserved during tumor progression of breast cancer , 2015, BMC Cancer.
[12] H. Hollema,et al. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. , 2015, Gynecologic oncology.
[13] Stephen T. C. Wong,et al. Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. , 2015, American journal of physiology. Cell physiology.
[14] J. Karamchandani,et al. Metastatic ovarian carcinoma to the brain: An approach to identification and classification for neuropathologists , 2015, Neuropathology : official journal of the Japanese Society of Neuropathology.
[15] Hong Cheng,et al. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer , 2014, BMC Cancer.
[16] Lukyanova Ny,et al. Clinical significance of hormonal receptor status of malignant ovarian tumors. , 2014, Experimental oncology.
[17] B. Jabbari,et al. Brain metastasis from ovarian cancer: a systematic review , 2014, Journal of Neuro-Oncology.
[18] Yiling Lu,et al. Predicting time to ovarian carcinoma recurrence using protein markers. , 2013, The Journal of clinical investigation.
[19] Tomoyoshi Soga,et al. Oncometabolites: linking altered metabolism with cancer. , 2013, The Journal of clinical investigation.
[20] H. Koizumi,et al. Proteomic analysis of differential protein expression by brain metastases of gynecological malignancies , 2013, Human Cell.
[21] M. Muckenthaler,et al. Novel mutations in the ferritin-L iron-responsive element that only mildly impair IRP binding cause hereditary hyperferritinaemia cataract syndrome , 2013, Orphanet Journal of Rare Diseases.
[22] M. Shimada,et al. Clinicopathologic features of brain metastases from gynecologic malignancies: a retrospective study of 139 cases (KCOG-G1001s trial). , 2013, Gynecologic oncology.
[23] K. Yoshihara,et al. Increased incidence of brain metastases in BRCA1‐related ovarian cancers , 2013, The journal of obstetrics and gynaecology research.
[24] Chih-Long Chang,et al. Brain metastases from epithelial ovarian carcinoma: evaluation of prognosis and managements - a Taiwanese Gynecologic Oncology Group (TGOG) study. , 2012, Gynecologic oncology.
[25] B. Piura,et al. Brain Metastases from Ovarian Carcinoma , 2011, ISRN oncology.
[26] A. Sood,et al. Multidrug Resistance Gene (MDR-1) and Risk of Brain Metastasis in Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer , 2011, American journal of clinical oncology.
[27] L. Selvaggi,et al. Central Nervous System Metastases From Epithelial Ovarian Cancer: Prognostic Factors and Outcomes , 2011, International Journal of Gynecologic Cancer.
[28] J. Smyth,et al. Higher Incidence of Isolated Brain Metastases in Ovarian Cancer Patients With Previous Early Breast Cancer , 2010, International Journal of Gynecologic Cancer.
[29] J. Brändstedt,et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival , 2010, Journal of ovarian research.
[30] G. Viale,et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers , 2010, Breast Cancer Research and Treatment.
[31] A. Reuss,et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.
[32] D. Boehmer,et al. Brain metastases in relapsed epithelial ovarian cancer after chemotherapy with pegylated liposomal doxorubicin. , 2008, Anticancer research.
[33] C. Fisher,et al. Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] P. Sabbatini,et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[35] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..